ABSTRACT
Several different criteria for adequacy in thyroid aspirates have been proposed. For lesions that lack abundant colloid (ie, colloid nodules), these include six groups each with 10 or more benign cells, 1,2 10 groups each with 20 or more cells, 3 six groups on at least two of six aspirates, 4 and eight groups on at least two slides. 5 In The Bethesda System for Reporting Thyroid Cytopathology, 6 adequacy criteria for a fine-needle aspirate (FNA) consist of six groups of 10 well-visualized follicle cells. While the data clearly show that these criteria separate patients into two groups with different risks of malignancy, there was little effort to rigorously compare these criteria with other thresholds or with other published adequacy criteria before being incorporated into the Bethesda system. Subsequent
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Renshaw and Gould / NIFTP aNd ThyroId FNa adequacy studies have shown that these criteria are unnecessarily stringent and that patients with as little as 10 to 30 cells on direct smears 7, 8 and even one cell on ThinPrep (Hologic, Marlborough, MA) preparations 9 are at no increased risk of malignancy compared with patients with 60 or more cells and that use of these lower thresholds can significantly reduce the nondiagnostic rate (by as much as 40%-67%), [7] [8] [9] sparing a significant number of patients the risk, cost, and inconvenience of a repeat biopsy from which they derive no benefit.
Recently, it has been recognized that some tumors that were previously classified as papillary carcinomas have little to any risk of progression, and these tumors have been reclassified as noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP). 10 Previous studies have shown that using this new classification will likely lead to a significant reduction in the risk of malignancy for indeterminate diagnoses in thyroid FNA. [11] [12] [13] However, there is less information available concerning its impact on the risk of malignancy for either benign or nondiagnostic diagnoses. We sought to determine the impact of NIFTP on the risk of malignancy of benign and nondiagnostic diagnoses and whether lowering the threshold for adequacy from 60 to 10 cells was affected by NIFTP in a large series of cases with histologic follow-up.
Materials and Methods
Benign and nondiagnostic thyroid FNAs interpreted at our hospital from 1997 through June 2016 were reviewed, and the results correlated with the results of histologic follow-up. All cases were initially classified or reclassified (for cases predating Bethesda) according to the most recent Bethesda system for reporting thyroid cytopathology. 6 Cases with a malignancy on follow-up were reviewed along with their subsequent excision. Histologic resections were reclassified as NIFTP if they met the available criteria. 10 In addition, three different thresholds have been proposed for a better separation between nondiagnostic and benign cases: one cell, 10 cells, and 30 cells. [7] [8] [9] As a result, as previously described, 7, 8 cases with 10 to 60 well-visualized, benign-appearing, follicular cells without atypia or Hürthle cell change were subsequently reclassified as benign as part of the current study.
All aspirates were performed by clinicians. Approximately one-third of aspirates were performed in clinicians' offices without imaging studies. Between two and eight passes were made. Two-thirds of aspirates were performed in the radiology department, with the aid of ultrasound guidance and immediate evaluation. Direct smears were made in all cases, and all were alcohol fixed and stained with either the Papanicolaou or H&E stain. If sufficient material was obtained, cell blocks were also made.
All malignancies at resection were identified. Papillary carcinomas less than 1 cm that did not correspond to either the clinically identified nodule or the material in the aspirate were determined to be incidental and not included.
All cases in which a benign diagnosis was associated with a malignant diagnosis on resection were reviewed. If there were no cytologic features associated with the specific malignant diagnosis in a particular case, the case was classified as a sampling false-negative case. These cases were not further assessed to determine the reason for sampling. If there were features that have been associated with malignancy in the case on review, the case was classified as an interpretation error. Of the five interpretation errors, four were associated with a single group of atypical cells in the background of a benign aspirate that was papillary carcinoma on resection. In one case, the presence of a small area of increased microfollicles was present in an otherwise benign aspirate that was later diagnosed as follicular carcinoma.
Statistical analysis was performed using a χ 2 test and a threshold of .05.
Results
From 12,764 aspirates, there were 8,106 (64%) benign diagnoses with 412 resections (5%) and 1,888 (14.8%) nondiagnostic diagnoses with 329 (17%) resections ❚Table 1❚.
Before the use of NIFTP, there were 18 (4.3%) malignancies in the benign aspirates (14 papillary carcinomas and four follicular carcinomas, including 13 sampling and five interpretation errors). Of the 13 sampling errors, seven of the resections occurred more than 1 year after the aspiration. There were 39 (11.9%) malignancies in the nondiagnostic aspirates (34 papillary carcinomas, one follicular carcinoma, two Hürthle cell carcinomas, one poorly differentiated thyroid carcinoma, and one parathyroid carcinoma).
There were 12 NIFTP cases on review (eight in the benign aspirates and four in the nondiagnostic aspirates). After reclassification using NIFTP, there were 10 (2.4%) of 412 malignancies in the benign aspirates and 35 (10.6%) of 329 malignancies in the nondiagnostic aspirates.
There were 94 cases with 10 to 60 cells without atypia or Hürthle cell change originally classified as nondiagnostic, including five malignant cases (three of which were NIFTP). When these cases were reclassified as benign rather than nondiagnostic, the overall nondiagnostic rate was reduced 30%, and the malignancy rate for a benign aspirate without recognizing NIFTP was 4.5% (23/506) but decreased to 2.3% (12/506, P = 1.0) when NIFTP cases were recognized ❚Table 2❚. For comparison, there were 45 nondiagnostic aspirates that contained cyst contents only (numerous macrophages without follicular cells), six of which were associated with papillary carcinomas (no cases of NIFTP). If these cases were diagnosed as benign, the risk of malignancy for a benign aspirate was 24 (5.2%) of 457 (P = .63) when aspirates with cyst contents only were diagnosed as benign.
Discussion
When the adequacy criteria that The Bethesda System for Reporting Thyroid Cytopathology 6 eventually adopted of six groups of 10 well-visualized follicle cells were originally developed by Goellner et al 1 and Grant et al 2 in the 1980s, most aspirates were performed without image guidance, and as a result, the average size of the nodules that were aspirated was relatively large (or at least large enough to be palpated). Over time, however, practices have changed, and as outlined in the American Thyroid Association guidelines, 14 most thyroid FNAs performed today are done using ultrasound guidance, and as a result, the average size of the nodules that can be identified and subsequently aspirated has grown smaller, since it may only be identified with imaging techniques. It is unclear if this change in practice has affected the utility of the original criteria that Goellner et al 1 and Grant et al 2 developed, mainly because those original adequacy criteria were never fully tested. However, subsequent publications have clearly shown that these criteria are likely too stringent. Aspirates with as little as 10 to 30 cells on direct smears 7, 8 and even one cell on ThinPrep preparations 9 are at no increased risk of malignancy compared with patients with 60 or more cells, and use of these lower threshold can reduce the nondiagnostic rate by 40% to 67% [7] [8] [9] and spare a significant number of patients the risk, cost, and inconvenience of a repeat biopsy from which they derive no benefit. In addition, there is now a body of literature from our clinical colleagues suggesting that the risk of malignancy of a nondiagnostic aspirate is so low that none of these patients need to undergo repeat biopsy but can safely be followed. [15] [16] [17] [18] Since a relatively large number of patients who are not at increased risk of malignancy are being misclassified as nondiagnostic using the current recommended criteria, this likely explains the very low risk of malignancy that the clinicians are identifying. However, by setting adequacy criteria too stringently, cytologists may be leading to a situation where in some practices, patients who are not at any increased risk are getting repeat biopsies, and patients in other practices who are at increased risk are not getting the repeat biopsy that they need.
Nevertheless, although every publication to date has shown that changing the threshold for adequacy from 60 to 10 cells does not significantly increase the false-negative rate for a benign diagnosis, a few additional patients with malignancies are usually misclassified as benign using these criteria. However, the definition of malignancy in the thyroid is also undergoing change, 10 and this has been shown to lead to very different risks of malignancy for patients with indeterminate diagnoses. [11] [12] [13] These same studies suggest that NIFTP may also have an impact on benign and nondiagnostic aspirates. In particular, NIFTP may comprise at least 25% of the "malignancies" associated with a benign aspirate. 12 However, the number of cases with histologic follow-up is limited, and there was no analysis of alternative diagnostic criteria. Our data address this. We also found that NIFTP comprised a significant percentage (44%) of the "malignancies" associated with a benign aspirate. In addition, NIFTP cases were commonly associated with 10 to 60 benign follicular cells in nondiagnostic cases. When cases of NIFTP are identified and classified as benign, the overall malignancy rate for a benign diagnosis dropped to 2.3% when the threshold for adequacy was reduced to 10 cells without atypia or Hürthle cell change. Thus, the distribution of NIFTP cases in benign and nondiagnostic aspirates is not uniform, and most of the "malignancies" that were identified in patients with 10 to 60 benign follicle cells and many of the benign aspirates with 60 or more cells were NIFTP. This finding is not surprising. The cytologic features of NIFTP by definition vary, and it is possible to obtain cells from NIFTP cases that appear very benign. This finding should also be reassuring to cytologists who might be uncomfortable with these less stringent criteria. For comparison, many clinicians and cytologists believe that patients with cyst contents alone (macrophages without any follicular cells) are at a low risk of malignancy. In our study, there were 45 such cases, and six were associated with papillary carcinoma and none with NIFTP. Diagnosing such lesions as benign resulted in more false-negative cases and a higher risk of malignancy for a benign aspirate than using a threshold of 10 benign follicular cells, although the differences were not statistically significant. In particular, the recognition of NIFTP did not lower the risk of malignancy for aspirates composed of cyst contents. As a result, it would seem much more prudent to reduce the nondiagnostic rate by reducing the number of follicle cells required for an adequate sample rather than diagnosing cyst contents alone as benign.
Previous studies have also shown that most false-negative thyroid FNAs are papillary carcinoma. 19 However, these previous studies did not clearly distinguish between sampling and interpretive error. Our data clearly show the most common cause of a false-negative case is sampling error. Whether this sampling error results from failing to target the correct nodule 20 or the inability to obtain diagnostic material from the correct nodule is not known. In more than half of these sampling errors, the resection occurred more than 1 year after the aspiration, raising the possibility that the carcinoma arose during that time interval. Regardless, this result strongly suggests that improvements in sensitivity are more likely to arise from improvements in sampling than in new or more accurate diagnostic criteria or additional ancillary studies including molecular tests.
In conclusion, with NIFTP, reducing the threshold for adequacy from 60 to 10 cells led to a nonsignificant decrease in the risk of malignancy of a benign aspirate to (2.3%). Thyroid FNAs with 10 to 60 benign cells without atypia or Hürthle cell change should be diagnosed as benign, and these patients (30%-67% of all nondiagnostic aspirates) should be spared a repeat biopsy from which they derive no benefit.
